{"DataElement":{"publicId":"3601066","version":"1","preferredName":"Acute Graft Versus Host Disease Preparative Regimen Finished Pharmaceutical Product Sirolimus Occurrence Indicator","preferredDefinition":"The indicator that describes whether or not sirolimus was used after the start of the preparative regimen to prevent acute GVHD.","longName":"2594434v1.0:2784450v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2594434","version":"1","preferredName":"Acute Graft Versus Host Disease Preparative Regimen Finished Pharmaceutical Product Sirolimus Occurrence","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling._A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)_Occurrence; an instance of something happening.","longName":"AGVHD_PRP_SIR_OCR","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2594377","version":"1","preferredName":"Acute Graft Versus Host Disease Preparative Regimen Finished Pharmaceutical Product","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation.:The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill\r\ndiseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not\r\noccur.:A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling.","longName":"C4980:C61155:C42639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Finished Pharmaceutical Product","conceptCode":"C42639","definition":"A pharmaceutical product that has undergone all stages of production and testing, including packaging in its final container and labelling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2920B866-F5D4-014B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-10","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-10","modifiedBy":"CCURATOR","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2594432","version":"1","preferredName":"Sirolimus Occurrence","preferredDefinition":"A drug used to help prevent rejection of organ and bone marrow transplants by the body.:Occurrence; an instance of something happening.","longName":"C1212:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2926900F-7DB1-55B2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-10","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-10","modifiedBy":"ONEDATA","dateModified":"2007-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2182571","version":"1","preferredName":"Pharmacologic Substance","preferredDefinition":"A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.","longName":"PHARMACOLOGIC SUBSTANCE","context":"caCORE","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"D727D9B9-FB5E-1E8C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-04-03","endDate":null,"createdBy":"DWARZEL","dateCreated":"2004-04-03","modifiedBy":"DWARZEL","dateModified":"2004-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2926900F-7DC2-55B2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-04-28","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-02-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2784450","version":"1","preferredName":"Yes No Unk ND NA Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.","longName":"Y_N_U_ND_NA_IND","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E072-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E07E-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E08A-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E0A2-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Not Done","valueDescription":"Not Done: C49484","ValueMeaning":{"publicId":"2579172","version":"1","preferredName":"Not Done: C49484","longName":"2579172","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or completed.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0251-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-04","modifiedBy":"KUMMEROA","dateModified":"2022-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59223A59-341F-0A9E-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-10-13","modifiedBy":"ALEYR","dateModified":"2008-10-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2784449","version":"1","preferredName":"Yes No Unknown Not Done Not Applicable Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Not known, not observed, not recorded, or refused.:Indicates a task, process or examination that has either not been initiated or completed.:Determination that a value is not relevant in the current context.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C49488:C49487:C17998:C49484:C4","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56A428C5-E04C-6CDD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ONEDATA","dateModified":"2008-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"56A428C5-E05D-6CDD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"GDEEN","dateModified":"2023-05-12","changeDescription":". Modified def to preferred def per caDSR meeting. No versioning needed. AK 2/8/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Was sirolimus (Rapamycin, Rap","type":"Preferred Question Text","description":"Was sirolimus (Rapamycin, Rapamune) used after the start of the preparative regimen to prevent acute GVHD or graft rejection?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CB00BAF6-72C0-88B8-E040-BB89AD4304FE","latestVersionIndicator":"Yes","beginDate":"2012-10-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-10-01","modifiedBy":"KUMMEROA","dateModified":"2021-03-16","changeDescription":". 2021-3-16 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}